Search research articles
Contact Us
Filters
Showing results (1-10 of 94) with videos related to
Page
of 10
Sort By:
Health Affairs (Project Hope)
|
May 22, 2003
The efficient use of pharmaceuticals: does Europe have any lessons for a Medicare drug benefit?
Adrian Towse
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
July 13, 2010
Net clinical benefit: the art and science of jointly estimating benefits and risks of medical treatment
Adrian Towse
BMJ (Clinical Research Ed.)
|
January 28, 2009
Should NICE's threshold range for cost per QALY be raised? Yes
Adrian Towse
Health Economics
|
June 28, 2007
If it ain't broke, don't price fix it: the OFT and the PPRS
Adrian Towse
British Journal of Clinical Pharmacology
|
August 19, 2010
Value based pricing, research and development, and patient access schemes. Will the United Kingdom get it right or wrong?
Adrian Towse
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
October 8, 2022
Real Option Value: Should We Opt In or Out?
Adrian Towse
Pharmacoeconomics
|
November 30, 2002
National Institute for Clinical Excellence (NICE): Is economic appraisal working?
Adrian Towse, Clive Pritchard
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care
|
February 17, 2019
Is rate of return pricing a useful approach when value-based pricing is not appropriate?
Michael Drummond, Adrian Towse
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care
|
November 2, 2011
Is it time to reconsider the role of patient co-payments for pharmaceuticals in Europe?
Michael Drummond, Adrian Towse
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
June 15, 2019
Uncertainty and Cures: Discontinuation, Irreversibility, and Outcomes-Based Payments: What Is Different About a One-Off Treatment?
Adrian Towse, Elisabeth Fenwick
Page
of 10
Search research articles
Search
Showing results (1-10 of 94) with videos related to
Sort By:
Page
of 10
Health Affairs (Project Hope)
|
May 22, 2003
The efficient use of pharmaceuticals: does Europe have any lessons for a Medicare drug benefit?
Adrian Towse
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
July 13, 2010
Net clinical benefit: the art and science of jointly estimating benefits and risks of medical treatment
Adrian Towse
BMJ (Clinical Research Ed.)
|
January 28, 2009
Should NICE's threshold range for cost per QALY be raised? Yes
Adrian Towse
Health Economics
|
June 28, 2007
If it ain't broke, don't price fix it: the OFT and the PPRS
Adrian Towse
British Journal of Clinical Pharmacology
|
August 19, 2010
Value based pricing, research and development, and patient access schemes. Will the United Kingdom get it right or wrong?
Adrian Towse
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
October 8, 2022
Real Option Value: Should We Opt In or Out?
Adrian Towse
Pharmacoeconomics
|
November 30, 2002
National Institute for Clinical Excellence (NICE): Is economic appraisal working?
Adrian Towse, Clive Pritchard
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care
|
February 17, 2019
Is rate of return pricing a useful approach when value-based pricing is not appropriate?
Michael Drummond, Adrian Towse
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care
|
November 2, 2011
Is it time to reconsider the role of patient co-payments for pharmaceuticals in Europe?
Michael Drummond, Adrian Towse
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
June 15, 2019
Uncertainty and Cures: Discontinuation, Irreversibility, and Outcomes-Based Payments: What Is Different About a One-Off Treatment?
Adrian Towse, Elisabeth Fenwick
Page
of 10